shutterstock_1886551888_emily_frost
2 November 2023GenericsMarisa Woutersen

Setback for Alvogen in approval bid for IBS generic

District court denies Norwich’s motion to compel FDA to grant approval for its version of popular IBS medication | Court also grants summary judgment in favour of FDA and Norwich’s competitor.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
28 August 2018   Generics maker Alvogen secured a patent win at a US court last week, despite the judge finding that the company had infringed patents covering an opioid treatment.
Generics
17 December 2015   Life sciences company Purdue Pharma is attempting to thwart rival Alvogen’s attempt to market a generic version of its Butrans (buprenorphine) product.

More on this story

Americas
28 August 2018   Generics maker Alvogen secured a patent win at a US court last week, despite the judge finding that the company had infringed patents covering an opioid treatment.
Generics
17 December 2015   Life sciences company Purdue Pharma is attempting to thwart rival Alvogen’s attempt to market a generic version of its Butrans (buprenorphine) product.

More on this story

Americas
28 August 2018   Generics maker Alvogen secured a patent win at a US court last week, despite the judge finding that the company had infringed patents covering an opioid treatment.
Generics
17 December 2015   Life sciences company Purdue Pharma is attempting to thwart rival Alvogen’s attempt to market a generic version of its Butrans (buprenorphine) product.